GemPharmatech Co., Ltd. (SHA:688046)

China · Delayed Price · Currency is CNY

29.79

-0.78 (-2.55%)

At close: Sep 11, 2026

Market Cap	12.19B +56.1%
Revenue (ttm)	878.13M +21.7%
Net Income	182.55M +74.9%
EPS	0.45 +79.3%
Shares Out	409.16M
PE Ratio	65.96
Forward PE	60.80
Dividend	0.22 (0.71%)
Ex-Dividend Date	Jun 9, 2026

Volume	7,859,626
Open	30.57
Previous Close	30.57
Day's Range	28.91 - 30.58
52-Week Range	12.89 - 43.47
Beta	0.90
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 20, 2026

About GemPharmatech

GemPharmatech Co., Ltd., a contract research organization, provides genetically engineered mouse models and preclinical research services to the scientific community worldwide. The company offers mouse models, including knockout and conditional knockout mouse, knock-in mouse, point-mutation mouse, transgenic mouse, immunodeficient mouse, germ-free mouse, and tool mice models, as well as operates wild mouse project. It also provides custom model generation, preclinical testing, germ-free and microbiome, cell lines and customization, custom breed... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2017

Employees 1,692

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 688046

Full Company Profile

Financial Performance

In 2025, GemPharmatech's revenue was 793.39 million, an increase of 15.51% compared to the previous year's 686.84 million. Earnings were 142.64 million, an increase of 29.88%.

Financial Statements